Recital 23, Decision_act (EU) 2022/1388

In forcesince 23 Jun 2022

Having regard to the foregoing considerations, the Commission considers that risk mitigation measures to address the risk of primary and secondary poisoning incidents from the use of biocidal products containing alphachloralose, in the form placed on the market, should, exceptionally, pending the conclusion of the evaluation of the application for renewal of the approval of alphachloralose, depend on the particular circumstances and available scientifically validated evidence of the occurrence of secondary poisoning incidents in the individual Member States. Some Member States might, for example, consider it necessary to restrict use of biocidal products containing alphachloralose to trained professionals while others might consider that additional labelling requirements suffice.